Following the FDA's July 27, 2026 NDA acceptance, PolyPid has achieved the milestones required for the $30 million in upfront and near-term milestone payments from Azurity. Advancing Kynatrix Pipeline Beyond D-PLEX100: Beyond D-PLEX100, PolyPid continues to advance its proprietary Kynatrix technology through additional pipeline programs, including its long-acting metabolic program and additional infection opportunities beyond prevention. Research and development activity in the second quarter of 2026 primarily reflects ongoing NDA-related activities and continued commercial readiness preparation. General and administrative expenses for the three months ended June 30, 2026, were $1.3 million, compared to $2.5 million for the same period of 2025. General and administrative expenses for the six months ended June 30, 2026, were $2.9 million, compared to $3.7 million for the same period of 2025.